NVO - US Prescriptions Race For Weight Loss Drugs - Eli Lilly's Zepbound Overtakes Novo Nordisk's Wegovy | Benzinga
Eli Lilly And Co’s (NYSE:LLY) much-in-demand weight-loss drug Zepbound (tirzepatide) surged ahead with 77,590 new prescriptions in the U.S. for the week ending March 8, surpassing Novo Nordisk A/S’s (NYSE:NVO) rival obesity medicine Wegovy (semglutide) for the first time since its launch.
Despite filling 6,000 fewer prescriptions than Wegovy that week, Lilly’s Zepbound managed to claim the top spot, according to data from IQVIA.
Since its U.S. launch in December, Zepbound has been gaining momentum, closing the gap with Novo’s Wegovy, which was approved over two years earlier.
However, Novo still holds the lead in total weekly prescriptions over Zepbound by 25,307, ...